Carcinosarcoma of the parotid is a rare biphasic malignant neoplasm comprised of both carcinomatous and sarcomatous components representing approximately 0.4% of all malignant salivary gland neoplasms. We report a case of a 55-year-old Caucasian man who presented with a progressively enlarging left facial mass. Histopathological evaluation of the tumoral tissue revealed a high grade, mixed epithelial and mesenchymal malignant tumor, most consistent with a carcinosarcoma of the parotid. Morphoproteomic analysis was performed and revealed expression of secreted protein acidic and rich in cysteine (SPARC); glioma-associated oncogen protein 2 (Gli2); and phosphorylated signal transducer and activator of transcription (p-STAT3 [Tyr705]) in the carcinomatous and malignant mesenchymal components. These aforementioned markers have been linked to the epithelial–mesenchymal transition in which epithelial cells lose their characteristics and phenotypically become mesenchymal cells. This finding allows us to further understand the biology of the 2 cellular components of the carcinosarcoma as having a monoclonal origin.
GneppDR. Malignant mixed tumors of the salivary glands: a review. Pathol Annu. 1993;28(pt 1):279-328.
2.
LiessBDHirschiSZitschRPFrazierSKonradA. Carcinosarcoma of the parotid gland: report of a case with immunohistochemical findings. Ann Otol Rhinol. 2007;116:702-704.
3.
VékonyHLeemansCRYlstraBMeijerGAvan der WaalIBloemenaE. Salivary gland carcinosarcoma: oligonucleotide array CGH reveals similar genomic profiles in epithelial and mesenchymal components. Oral Oncol. 2009;45:259-265.
4.
BrownRE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med. 2009;133:568-579.
5.
BrownRE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics. 2005;2:337-348.
6.
StaffieriCMarioniGFerraroSMMarinoFStaffieriA. Carcinosarcoma de novo of the parotid gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;104:e35-e40.
7.
KirklinJWMcDonaldJRHarringtonSW. Parotid tumors: histopathology, clinical behavior and end results. Surg Gynecol Obstet. 1951;92:721-733.
8.
UeoTKashimaKDaaT. Carcinosarcoma of the parotid gland: an unusual case with large-cell neuroendocrine carcinoma and rhabdomyosarcoma. APMIS. 2005;113:456-464.
TakiNHLaverNQuintoTWeinRO. Carcinosarcoma de novo of the parotid gland: case report. Head Neck. 2013;35:E161-E163.
11.
StephenJBatsakisJGLunaMAvon der HeydenUByersRM. True malignant mixed tumors (carcinosarcoma) of salivary glands. Oral Surg Oral Med Oral Pathol. 1986;61:597-602.
12.
PodhajcerOLBenedettiLGGirottiMRPradaFSalvatierraELleraAS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008;27:691-705.
13.
ThieryJP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
14.
TalbotLJBhattacharyaSDKuoPC. Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 2012;3:117-136.
15.
OzdamarBBoseRBarrios-RodilesMWangHRZhangYWranaJL. Regulation of the polarity protein Par6 by TGFβ receptors controls epitelial cell plasticity. Science. 2005;307:1603-1609.
16.
PeinadoHBallestarEEstellerMCanoA. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol. 2004;24:306-319.
ZhaoYYanQLongXChenXWangY. Vimentin affects the mobility and invasiveness of prostate cancer cell. Cell Biochem Funct. 2008;26:571-577.
19.
MoustakasAHeldinP. TGFβ and matrix-regulated epithelial to mesenchymal transition. Biochim Biophys Acta. 2014;1840:2621-2634.
20.
IllmanSALehtiKKeski-OjaJLohiJ. Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci. 2006;199(pt 18):3856-3865.
21.
LeivonenSKChantryAHakkinenLHanJKahariVM. Smad3 mediates transforming growth factor-β-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts. Evidence for cross-talk between Smad3 and p38 signaling pathways. J Biol Chem. 2002;277:46338-46346.
22.
GargM. Epithelial-mesenchymal transition—activating transcription factors—multifunctional regulators in cancer. World J Stem Cells. 2013;5:188-195.
23.
ChenXLingalaSNoltaJZernMAWuJ. Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations. J Hepatol. 2011;55:838-845.
24.
YueDLiHCheJ. Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J Exp Clin Cancer Res. 2014;33:34.
25.
MaitahMYAliSAhmadAGadgeelSSarkarFH. Up-regulation of Sonic Hedgehog contributes to TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells. PLoS One. 2011;6(1):e16068.
26.
LiZPanDLiY. Effect of TGF-β on Gli2 expression in HL60 and U937 cell lines. Mol Med Rep. 2012;5:1245-1250.
27.
ThieryJPAcloqueHHuangRYNietoMA. Epithelial-mesenchymal transition in development and disease. Cell. 2009;139:871-890.
28.
ChungSSGiehlNWuYVadgamaJV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 2014;44:403-411.
29.
MiaoJWLiuLJHuangJ. Interleukin-6-induced epithelial-mesenchymal transition through signal transducer and activator of transcription 3 in human cervical carcinoma. Int J Oncol. 2014;45:165-176.
30.
TengJWangXXuZTangN. HBx-dependent activation of Twist mediates STAT3 control of epithelium-mesenchymal transition of liver cells. J Cell Biochem. 2013;114:1097-1104.
31.
FowlerMHFowlerJDucatmanBBarnesLHuntJL. Malignant mixed tumors of the salivary gland: a study of loss of heterozygosity in tumor suppressor genes. Mod Pathol. 2006;19:350-355.
32.
ThompsonLChangBBarskySH. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am J Surg Pathol. 1996;20:277-285.
33.
MatsumotoTFujiiHArakawaA. Loss of heterozygosity analysis shows monoclonal evolution with frequent genetic progression and divergence in esophageal carcinosarcoma. Hum Pathol. 2004;35:322-327.
34.
Paniz MondolfiAEJourGJohnsonM. Primary cutaneous carcinosarcoma: insights into its clonal origin and mutational patter expression analysis through next-generation sequencing. Hum Pathol. 2013;44:2853-2860.
35.
ThomasVTHinsonSKonduriK. Epithelial-mesenchymal transition in pulmonary carcinosarcoma: case report and literature review. Ther Adv Med Oncol. 2012;4:31-37.
36.
CastillaMAMoreno-BuenoGRomero-PérezL. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol. 2011;223:72-80.
37.
DykeJMCrookMLPlattenMStewartCJ. Extravascular migratory metastasis in gynaecological carcinosarcoma. Histopathology. 2014;65:363-370.
38.
SungCOChoiHLeeKWKimSH. Sarcomatoid carcinoma represents a complete phenotype with various pathways of epithelial mesenchymal transition. J Clin Pathol. 2013;66:601-606.
39.
StewartCJMcCluggageWG. Epithelial-mesenchymal transition in carcinomas of the female genital tract. Histopathology. 2013;62:31-43.
40.
SaegusaMHashimuraMKuwataTOkayasuI. Requirement of the Akt/β-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol. 2009;174:2107-2115.
